Industry

Transcatheter aortic valve replacement using an Edwards Lifesciences valve system demonstrated encouraging outcomes in patients with severe aortic regurgitation. The data suggest TAVR may be a viable treatment option for this traditionally surgical patient population.

Digest: Severe AR has been a relative contraindication for TAVR due to anatomical challenges, and positive data could expand the treatment population and market for Edwards' valve technology.

The SMART trial's 3-year results showed that self-expanding supra-annular TAVR valves (Evolut platform, Medtronic) demonstrated superior hemodynamics and less thrombosis compared to balloon-expandable valves (Sapien platform, Edwards Lifesciences) in patients with small aortic annuli (≤430 mm²). There was no difference in the composite clinical endpoint of mortality, disabling stroke, or heart failure rehospitalization between groups (self-expanding 25.4% vs balloon-expandable 22.6%; HR 1.13, 95% CI 0.83-1.53, P=0.44).

Digest: These extended follow-up data support the use of self-expanding supra-annular valves for improved hemodynamic performance in small annuli patients, particularly relevant for lower-risk and younger TAVR candidates where long-term valve function is critical.

A study demonstrates that redo transcatheter aortic valve replacement using balloon-expandable valves is associated with favorable clinical outcomes and key procedural improvements. The findings support the safety and efficacy of repeat TAVR procedures in patients with failed bioprosthetic valves.

Digest: As the TAVR population ages and device durability becomes critical, establishing safety profiles for redo TAVR with specific valve platforms helps guide treatment decisions for structural valve degeneration.

TAVR valve implant depth significantly influences post-procedural outcomes including paravalvular leak, conduction abnormalities requiring permanent pacemaker, and coronary obstruction risk. Optimal implantation depth varies by valve platform, with higher implantation generally associated with reduced paravalvular regurgitation but increased pacemaker rates, while deeper implantation may increase coronary occlusion risk particularly in valve-in-valve procedures.

Digest: Precise implant depth optimization is a modifiable procedural factor that directly impacts major TAVR complications and may influence valve selection and procedural planning across risk stratifications.

Edwards Lifesciences' Resilia tissue, an integrity preservation technology for bioprosthetic heart valves, demonstrates favorable long-term durability outcomes. The tissue treatment is designed to reduce calcium buildup and improve structural valve deterioration resistance compared to conventional tissue.

Digest: Long-term durability data for Resilia tissue is critical for structural heart professionals evaluating valve choice in younger, lower-risk patients where extended valve longevity directly impacts reintervention rates and lifetime management strategies.

A study comparing outcomes of redo TAVR procedures found no significant differences between supra-annular and intra-annular valve designs. The findings suggest that valve positioning strategy does not substantially impact clinical outcomes in patients requiring repeat transcatheter aortic valve replacement.

Digest: This evidence supports flexibility in valve selection for redo TAVR procedures, potentially influencing procedural planning and device choice in the growing population of patients with failed bioprosthetic valves.